Active clinical trials for "Developmental Disabilities"

This study will determine the effectiveness of mirtazapine in reducing anxiety in children with autistic disorder, Asperger's disorder and Pervasive Developmental Disorder.

The purpose of this study is to develop biomarkers for central nervous system BH4 concentration in children with autism so they can be easily screened to determine if they may benefit from BH4 supplementation. Kuvan is a synthetic form of BH4. BH4 is an enzyme cofactor that is essential for several critical metabolic functions.

The purpose of the study is to evaluate the safety and efficacy of oral melatonin in improving sleep continuity in children with epilepsy and neurodevelopmental delay who have chronic insomnia by comparing Fast Release Melatonin (FR MLT) to placebo and Timed Release Melatonin (TR MLT) with placebo in a randomized cross-over design trial.

This study will develop and test a treatment aimed at reducing anxiety in social situations for children and adolescents with autism spectrum disorders.

The purpose of this study is to evaluate the safety and tolerability of memantine in pediatric (6-12 years old) patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and to identify responders for participation in a follow-up randomized withdrawal study.

This study will examine the effectiveness of riluzole for treating Obsessive-Compulsive Disorder in Youth, Including those with Autism Spectrum Disorders.

The purpose of this study is to develop a better tolerated and more effective pharmacologic treatment for individuals with Asperger's Disorder and Pervasive Developmental Disorder. This is an open-label investigation of aripiprazole in the management of the maladaptive behaviors of autistic disorder. We hypothesize that aripiprazole will be effective for reducing aggression and repetitive behavior.

The purpose of this research is to study the pharmacokinetics of risperidone in a group of pediatric patients with Pervasive Developmental Disorder (PDD). The study will determine how much risperidone and its breakdown product, 9-hydroxy-risperidone, is in the blood following the patient's usual daily dose. The study is designed to look at how fast children absorb, breakdown, and eliminate risperidone.

The objective of this study is to test whether adding the parent training program using the relationship-based approach could help the children with development disabilities (DDs) would confer additional benefits over routine clinical care available to both groups in terms of improving their development and reducing behavior problems.

This pilot project is a cooperative effort between the Leisure in Fun Environments (LIFE) Program and the Specialized Communication Resources for Children (SCRC) Program at the Rehabilitation Centre for Children (RCC). The investigators will blend and enhance two pre-existing programs in order to provide a new, specialized program for parents of children with ASD or developmental delay. The two programs that will be blended together are "Promoting Flexible Thinking and Interaction with Your Child at Home" and "Saturday Cooking Club." This new program will be a series of ten workshops that alternates between "parents only" learning sessions and practical "cooking club" sessions that allow parents to focus on practicing what they are learning with their child. These programs are based on the principles of Relationship Development Intervention (RDI®), which focuses on providing opportunities to establish a guided participation relationship, which will lead to development of dynamic intelligence and important social thinking abilities. The program is individualized to each child and builds on the principles of typical development to assist the child in achieving social competence. Using this program, children are expected to develop sociability in a naturally progressing order of complexity.